

Big Pharma Split Corp.

QUARTERLY PORTFOLIO DISCLOSURE

as at March 31, 2020

Total Assets

The total assets of the Big Pharma Split Corp. was \$23,176,909 and includes the value of the Preferred Shares.

Summary of Investment Portfolio

Sector Allocation	% of Total Assets
Pharmaceuticals	81.2
Biotechnology	19.9
Total Portfolio Assets	101.1
Cash and other assets and liabilities	5.6
Foreign currency forwards	(6.7)
Total Asset Value	100.0

Portfolio Allocation	% of Total Assets
Common Shares	71.7
ADRs	30.5
Equity options	(1.1)
Total Portfolio Assets	101.1
Cash and other assets and liabilities	5.6
Foreign currency forwards	(6.7)
Total Asset Value	100.0

Portfolio Breakdown

Top Holdings	% of Total Assets
Merck & Co., Inc.	10.5
AstraZeneca PLC	10.4
Eli Lilly and Company	10.4
Johnson & Johnson	10.3
Bristol-Myers Squibb Company	10.3
Pfizer Inc.	10.2
Amgen Inc.	10.2
GlaxoSmithKline PLC	10.1
Sanofi S.A.	10.0
AbbVie Inc.	9.8
Cash and other assets and liabilities	5.6
Market value of equity options	(1.1)
Foreign currency forwards	(6.7)

The summary of investment portfolio may change due to ongoing portfolio transactions of the investment fund. This quarterly update is available on our website at www.harvestportfolios.com.

Customer Service

416.649.4541
Toll: 1.866.998.8298

Address

610 Chartwell Road
Suite 204
Oakville, ON
L6J 4A5



Your trusted source for income and growth investments